Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Carme Solé-Blanch"'
Autor:
Chen Sun, Sofia España, Nina Richarz, Carme Solé-Blanch, Aram Boada, Anna Martinez-Cardús, Alan Chu, Zongwen Liu, Jose Luis Manzano
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundTargeted therapies and immunotherapy are currently considered the mainstay first-line treatment for advanced BRAF-mutated melanoma. However, the impact of treatment (targeted therapy and immunotherapy) and the prognostic factors are still n
Externí odkaz:
https://doaj.org/article/f5254ba3e2e04f07aeeaf49d379774ea
Autor:
Vicenç Ruiz de Porras, Adrià Bernat-Peguera, Clara Alcon, Fernando Laguia, Maria Fernández-Saorin, Natalia Jiménez, Ana Senan-Salinas, Carme Solé-Blanch, Andrea Feu, Mercedes Marín-Aguilera, Juan Carlos Pardo, Maria Ochoa-de-Olza, Joan Montero, Begoña Mellado, Albert Font
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background: Docetaxel remains the standard treatment for metastatic castration-resistant prostate cancer (mCRPC). However, resistance frequently emerges as a result of hyperactivation of the PI3K/AKT and the MEK/ERK pathways. Therefore, the inhibitio
Externí odkaz:
https://doaj.org/article/15a09439b35e4fa08388d66216c30dd7
Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
Autor:
Sofia España Fernandez, Chen Sun, Carme Solé-Blanch, Aram Boada, Anna Martínez-Cardús, José Luis Manzano
Publikováno v:
Pharmaceutics, Vol 15, Iss 3, p 823 (2023)
Introduction: Immune checkpoint inhibitors (ICIs) have radically changed the prognosis of several neoplasias, among them metastatic melanoma. In the past decade, some of these new drugs have appeared together with a new toxicity spectrum previously u
Externí odkaz:
https://doaj.org/article/b6f78230cf9a4065b82322977530907c